Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
Conditions: Positive Lymph Node; Prostate Adenocarcinoma; PSA Level Greater Than Zero; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage IIA Prostate Cancer AJCC v8; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 Interventions: Drug: Abiraterone Acetate; Drug: Apalutamide; Drug: Hormone Therapy; Drug: Prednisone; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsors: NRG Oncology; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Abiraterone Acetate | Adenocarcinoma | Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Prednisone | Prostate Cancer | Radiation Therapy | Research